$EVFM
Evofem Biosciences, Inc. Stock $evfm

$evfm Overview Financials Valuation SEC Filings Company Website

2020 Form 10-K Financial Statement

#000161883521000040 Filed on March 04, 2021

Income Statement

Concept	2020	2019 Q4	2019
Revenue	$446.0K	$0.00	$0.00
YoY Change
Cost Of Revenue	$468.0K		$0.00
YoY Change
Gross Profit	-$22.00K		$0.00
YoY Change
Gross Profit Margin	-4.93%
Selling, General & Admin	$86.55M	$9.440M	$30.51M
YoY Change	183.67%	81.19%	-10.86%
% of Gross Profit
Research & Development	$17.05M	$3.430M	$22.23M
YoY Change	-23.3%	-64.89%	-48.8%
% of Gross Profit
Depreciation & Amortization	$300.0K	$60.00K	$260.0K
YoY Change	15.38%	0.0%	0.0%
% of Gross Profit
Operating Expenses	$104.1M	$12.87M	$52.74M
YoY Change	97.32%	-14.08%	-32.07%
Operating Profit	-$103.6M		-$52.74M
YoY Change	96.47%		-32.07%
Interest Expense	$2.061M	$120.0K	$0.00
YoY Change		300.0%	-100.0%
% of Operating Profit
Other Income/Expense, Net	-$38.68M	$155.0K	-$27.29M
YoY Change	41.76%		-43.23%
Pretax Income	-$142.3M	-$12.72M	-$80.03M
YoY Change	77.82%	-15.09%	-36.34%
Income Tax	$4.000K	$0.00	$4.000K
% Of Pretax Income
Net Earnings	-$142.3M	-$12.72M	-$80.03M
YoY Change	77.81%	-15.11%	-36.34%
Net Earnings / Revenue	-31907.85%
Basic Earnings Per Share	-$2.12
Diluted Earnings Per Share	-$2.12	-$251.2K	-$1.989M
COMMON SHARES
Basic Shares Outstanding	67.16M shares	46.81M shares
Diluted Shares Outstanding	67.16M shares

Balance Sheet

Concept	2020	2019 Q4	2019
SHORT-TERM ASSETS
Cash & Short-Term Investments	$48.90M	$23.80M	$23.80M
YoY Change	105.46%	1730.77%	1730.77%
Cash & Equivalents	$48.90M	$15.57M	$15.60M
Short-Term Investments	$0.00	$8.200M	$8.200M
Other Short-Term Assets	$40.40M	$1.900M	$1.900M
YoY Change	2026.32%	171.43%	171.43%
Inventory	$7.200M	$0.00
Prepaid Expenses
Receivables	$1.100M	$0.00
Other Receivables	$200.0K
Total Short-Term Assets	$97.70M	$26.42M	$26.40M
YoY Change	270.08%	966.22%	956.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.20M	$394.0K	$600.0K
YoY Change	1766.67%	-33.56%	0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.000M	$1.320M	$1.100M
YoY Change	-9.09%	40.58%	175.0%
Total Long-Term Assets	$12.30M	$1.874M	$1.900M
YoY Change	547.37%	22.32%	26.67%
TOTAL ASSETS
Total Short-Term Assets	$97.70M	$26.42M	$26.40M
Total Long-Term Assets	$12.30M	$1.874M	$1.900M
Total Assets	$110.0M	$28.30M	$28.30M
YoY Change	288.69%	605.61%	607.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.60M	$6.008M	$6.000M
YoY Change	76.67%	-32.36%	-32.58%
Accrued Expenses	$13.30M	$2.784M	$6.700M
YoY Change	98.51%	-75.82%	-53.47%
Deferred Revenue
YoY Change
Short-Term Debt	$52.40M	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Long-Term Debt Due	$52.41M
YoY Change
Total Short-Term Liabilities	$77.30M	$12.66M	$12.70M
YoY Change	508.66%	-53.68%	-53.48%
LONG-TERM LIABILITIES
Long-Term Debt	$25.20M	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$6.100M	$0.00	$0.00
YoY Change
Total Long-Term Liabilities	$31.30M	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$77.30M	$12.66M	$12.70M
Total Long-Term Liabilities	$31.30M	$0.00	$0.00
Total Liabilities	$108.6M	$12.66M	$12.70M
YoY Change	755.12%	-53.74%	-53.65%
SHAREHOLDERS EQUITY
Retained Earnings		-$513.2M
YoY Change		18.48%
Common Stock		$528.8M
YoY Change		29.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.300M	$15.64M	$15.60M
YoY Change
Total Liabilities & Shareholders Equity	$110.0M	$28.30M	$28.30M
YoY Change	288.69%	605.61%	607.5%

Cashflow Statement

Concept	2020	2019 Q4	2019
OPERATING ACTIVITIES
Net Income	-$142.3M	-$12.72M	-$80.03M
YoY Change	77.81%	-15.11%	-36.34%
Depreciation, Depletion And Amortization	$300.0K	$60.00K	$260.0K
YoY Change	15.38%	0.0%	0.0%
Cash From Operating Activities	-$104.8M	-$13.45M	-$55.10M
YoY Change	90.26%	31.22%	-2.48%
INVESTING ACTIVITIES
Capital Expenditures	$2.254M	-$140.0K	$164.0K
YoY Change	1274.39%	1300.0%	2242.86%
Acquisitions
YoY Change
Other Investing Activities	$8.480M	-$4.480M	-$7.950M
YoY Change	-206.67%		-469.77%
Cash From Investing Activities	$6.229M	-$4.630M	-$8.115M
YoY Change	-176.76%	46200.0%	-478.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$154.2M	2.200M	$78.08M
YoY Change	97.53%	-540.0%	43.48%
NET CHANGE
Cash From Operating Activities	-$104.8M	-13.45M	-$55.10M
Cash From Investing Activities	$6.229M	-4.630M	-$8.115M
Cash From Financing Activities	$154.2M	2.200M	$78.08M
Net Change In Cash	$55.63M	-15.88M	$14.86M
YoY Change	274.23%	47.58%	24673.33%
FREE CASH FLOW
Cash From Operating Activities	-$104.8M	-$13.45M	-$55.10M
Capital Expenditures	$2.254M	-$140.0K	$164.0K
Free Cash Flow	-$107.1M	-$13.31M	-$55.26M
YoY Change	93.78%	29.98%	-2.21%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001618835
CY2015Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-36754
CY2020	dei	Entity Registrant Name EntityRegistrantName	EVOFEM BIOSCIENCES, INC.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-8527075
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	12400 High Bluff Drive
CY2020	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 600
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
CY2020	dei	City Area Code CityAreaCode	858
CY2020	dei	Local Phone Number LocalPhoneNumber	550-1900
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	true
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	190546003	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	83119033	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48892000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15571000	USD
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	22559000	USD
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	304000	USD
CY2020Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	0	USD
CY2019Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	8233000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1067000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	7162000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	0	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	18050000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2313000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	97730000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	26421000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4334000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	394000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6856000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	160000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1048000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1320000	USD
CY2020Q4	us-gaap	Assets Assets	109968000	USD
CY2019Q4	us-gaap	Assets Assets	28295000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10641000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6008000	USD
CY2020Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	52409000	USD
CY2019Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4476000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2784000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6514000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3670000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2290000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	197000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	953000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	0	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	77283000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12659000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6030000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2020Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	25211000	USD
CY2019Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	0	USD
CY2020Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	97000	USD
CY2019Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	0	USD
CY2020Q4	us-gaap	Liabilities Liabilities	108621000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	12659000	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0.0001
CY2019Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0.0001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	81351533	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	81351533	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48137880	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1347000	USD
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48137880	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	656827000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	528810000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-655488000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-513179000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	15636000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	109968000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	28295000	USD
CY2020	us-gaap	Revenues Revenues	446000	USD
CY2019	us-gaap	Revenues Revenues	0	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	468000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17050000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22230000	USD
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	56467000	USD
CY2019	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	10238000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30085000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20274000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	104070000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	52742000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-103624000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-52742000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	169000	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	458000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2082000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	301000	USD
CY2020	evfm	Loss On Issuance Of Financial Instruments LossOnIssuanceOfFinancialInstruments	64049000	USD
CY2019	evfm	Loss On Issuance Of Financial Instruments LossOnIssuanceOfFinancialInstruments	674000	USD
CY2020	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	27281000	USD
CY2019	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-27372000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-38681000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-27287000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-142305000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-80029000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-80033000	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.12
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.99
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	67157278	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40228517	shares
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-23356000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	60000	USD
CY2019	evfm	Stock Issued During Period Value Employee Stock Purchase Plans And Exercise Of Stock Options StockIssuedDuringPeriodValueEmployeeStockPurchasePlansAndExerciseOfStockOptions	392000	USD
CY2019	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	-1566000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	29726000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8579000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-80033000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	15636000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	103266000	USD
CY2020	evfm	Stock Issued During Period Value Employee Stock Purchase Plans And Exercise Of Stock Options StockIssuedDuringPeriodValueEmployeeStockPurchasePlansAndExerciseOfStockOptions	360000	USD
CY2020	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	-2869000	USD
CY2020	evfm	Short Swing Profit Disgorgement ShortSwingProfitDisgorgement	187000	USD
CY2020	evfm	Adjustments To Additional Paidin Capital Reclassificationof Warrants And Purchase Rights Liability AdjustmentsToAdditionalPaidinCapitalReclassificationofWarrantsAndPurchaseRightsLiability	11015000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12697000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-142309000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1347000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-142309000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-80033000	USD
CY2020	evfm	Loss On Issuance Of Purchase Rights LossOnIssuanceOfPurchaseRights	64049000	USD
CY2019	evfm	Loss On Issuance Of Purchase Rights LossOnIssuanceOfPurchaseRights	674000	USD
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-27281000	USD
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	27372000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	12697000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	8579000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	302000	USD
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	263000	USD
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-79000	USD
CY2020	us-gaap	Lease Cost LeaseCost	879000	USD
CY2019	us-gaap	Lease Cost LeaseCost	642000	USD
CY2020	us-gaap	Interest Expense InterestExpense	2061000	USD
CY2019	us-gaap	Interest Expense InterestExpense	0	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1067000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6010000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	17356000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	952000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4126000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2931000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2729000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-8775000	USD
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2844000	USD
CY2019	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	746000	USD
CY2020	evfm	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	493000	USD
CY2019	evfm	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	761000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-104829000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-55097000	USD
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	32000	USD
CY2020	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	250000	USD
CY2019	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	250000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2254000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	164000	USD
CY2020	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	0	USD
CY2019	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	8233000	USD
CY2020	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	8233000	USD
CY2019	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6229000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8115000	USD
CY2020	evfm	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	103738000	USD
CY2019	evfm	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	0	USD
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2000	USD
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6273000	USD
CY2020	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	75400000	USD
CY2020	evfm	Proceeds From Issuance Of Common Stock Net Of Commissions ProceedsFromIssuanceOfCommonStockNetOfCommissions	3781000	USD
CY2019	evfm	Proceeds From Issuance Of Common Stock Net Of Commissions ProceedsFromIssuanceOfCommonStockNetOfCommissions	2960000	USD
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	447000	USD
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	305000	USD
CY2019	evfm	Proceeds From Short Swing Profit Disgorgement ProceedsFromShortSwingProfitDisgorgement	0	USD
CY2020	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	50000000	USD
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2020	evfm	Proceeds From Short Swing Profit Disgorgement ProceedsFromShortSwingProfitDisgorgement	187000	USD
CY2019	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	4010000	USD
CY2020	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1060000	USD
CY2019	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1286000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2869000	USD
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1566000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	154226000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	78076000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	55626000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	14864000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16625000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1761000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72251000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16625000	USD
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	2000	USD
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	4000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	7618000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	802000	USD
CY2020	evfm	Financing Costs Included In Accounts Payable And Accrued Expense FinancingCostsIncludedInAccountsPayableAndAccruedExpense	0	USD
CY2019	evfm	Financing Costs Included In Accounts Payable And Accrued Expense FinancingCostsIncludedInAccountsPayableAndAccruedExpense	306000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	823000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	10000	USD
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Deposits in the Company’s checking, time deposit and investment accounts are maintained in federally insured financial institutions and are subject to federally insured limits or limits set by Securities Investor Protection Corporation. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the consolidated balance sheets.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances due to the financial position of the depository institutions in which these deposits are held.</span></div>The Company is also subject to credit risk related to its trade accounts receivable from product sales. Its customers are located in the United States and consist of wholesale distributors and a specialty retail pharmacy. The Company extends credit to its customers in the normal course of business after evaluating their overall financial condition, and evaluates the collectability of its accounts receivable by periodically reviewing the age of the receivables, the financial condition of its customers, and its past collection experience. Historically, the Company has not experienced any credit losses. As of December 31, 2020, based on the evaluation of these factors the Company did not record an allowance for doubtful accounts. For the year ended December 31, 2020, the Company’s three largest customers made up approximately 92% of its gross product sales and 95% of its trade accounts receivable balance as of December 31, 2020.
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the notes thereto. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ignificant estimates affecting amounts reported or disclosed in the consolidated financial statements include, but are not limited to: the assumptions used in measuring the revenue gross-to-net variable consideration items, the trade accounts receivable credit loss reserve estimate, the discount rate used in estimating the fair value of the lease right</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">use (ROU) assets and lease liabilities, the assumptions used in estimating the fair value of convertible notes, warrants and purchase rights issued, the useful lives of property and equipment, the recoverability of long-lived assets, clinical trial accruals, the assumptions used in estimating the fair value of stock-based compensation expense and in assessing the probability of achieving certain milestones associated with the performance-based restricted stock awards (performance-based RSAs). These assumptions are more fully described in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iebb07c74a932461b85389af05e42feaf_1809" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 3- Revenue Recognition</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iebb07c74a932461b85389af05e42feaf_1834" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 5- Convertible Notes</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iebb07c74a932461b85389af05e42feaf_154" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 7- Fair Value of Financial Instruments</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iebb07c74a932461b85389af05e42feaf_157" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 8- Commitments and Contingencies</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iebb07c74a932461b85389af05e42feaf_187" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 12- Stock-based Compensation</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances and adjusts when facts and circumstances dictate. The estimates are the basis for making judgments about the carrying values of </span></div>assets and liabilities and recorded expenses that are not readily apparent from other sources. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions.
CY2020	evfm	Reclassification Of Warrants And Purchase Rights To Equity ReclassificationOfWarrantsAndPurchaseRightsToEquity	11015000	USD
CY2019	evfm	Reclassification Of Warrants And Purchase Rights To Equity ReclassificationOfWarrantsAndPurchaseRightsToEquity	6120000	USD
CY2020	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2019	us-gaap	Stock Issued1 StockIssued1	416000	USD
CY2020	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has separated the presentation of selling and marketing expenses from the total general and administrative expenses in the current period consolidated statement of operations. To conform prior year amounts to the current period presentation, a total of $10.2 million was reclassified from general and administrative expenses to selling and marketing expenses for the year ended December 31, 2019.</span></div>
CY2020Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	103700000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48900000	USD
CY2020Q4	evfm	Working Capital Surplus Deficit WorkingCapitalSurplusDeficit	20400000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-655500000	USD
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	25000000.0	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48892000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15571000	USD
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	22559000	USD
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	304000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	800000	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	750000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72251000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16625000	USD
CY2020Q2	evfm	Purchase Agreement Maximum Amount Of Securities Purchasable Under Agreement PurchaseAgreementMaximumAmountOfSecuritiesPurchasableUnderAgreement	10000000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6900000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	8300000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	200000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	200000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2668000	USD
CY2020Q4	us-gaap	Inventory Gross InventoryGross	7162000	USD
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19646572	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11966220	shares
CY2020Q4	evfm	Product Revenue Variable Consideration Liability Current ProductRevenueVariableConsiderationLiabilityCurrent	1000000.0	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	332000	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	4162000	USD
CY2016Q3	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	1900000	USD
CY2016Q3	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	600000	USD
CY2016Q3	us-gaap	Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet	1300000	USD
CY2019Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	8233000	USD
CY2019Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	42000	USD
CY2019Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	8275000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	18050000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2313000	USD
CY2016Q3	evfm	Disposal Group Including Discontinued Operation Consideration Receivable Stated Rate DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableStatedRate	0.050
CY2016Q3	evfm	Disposal Group Including Discontinued Operation Consideration Receivable Annual Principal Payment DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableAnnualPrincipalPayment	300000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5485000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1243000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1151000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	849000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4334000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	394000	USD
CY2019	us-gaap	Depreciation Nonproduction DepreciationNonproduction	300000	USD
CY2020	us-gaap	Depreciation Nonproduction DepreciationNonproduction	300000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	800000	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	750000	USD
CY2020Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	34000	USD
CY2019Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	0	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1048000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1320000	USD
CY2020Q4	evfm	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	1417000	USD
CY2019Q4	evfm	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	585000	USD
CY2020Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	564000	USD
CY2019Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	0	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1631000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1652000	USD
CY2020Q4	evfm	Accrued Manufacturing Related Costs Current AccruedManufacturingRelatedCostsCurrent	498000	USD
CY2019Q4	evfm	Accrued Manufacturing Related Costs Current AccruedManufacturingRelatedCostsCurrent	0	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	366000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	547000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4476000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2784000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	70233000	USD
CY2020Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	50752000	USD
CY2020Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	50752000	USD
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	22588000	USD
CY2020Q2	evfm	Purchase Agreement Maximum Amount Of Securities Purchasable Under Agreement PurchaseAgreementMaximumAmountOfSecuritiesPurchasableUnderAgreement	10000000	USD
CY2019Q2	evfm	Adjustments To Additional Paidin Capital Reclassification Of Warrants AdjustmentsToAdditionalPaidinCapitalReclassificationOfWarrants	6900000	USD
CY2019Q2	evfm	Purchase Right Liability PurchaseRightLiability	3200000	USD
CY2020	evfm	Lessee Operating Lease Number Of Vehicles Leased LesseeOperatingLeaseNumberOfVehiclesLeased	76	vehicle
CY2019Q4	evfm	Office Square Footage OfficeSquareFootage	24474	sqft
CY2019Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2020Q2	evfm	Office Square Footage OfficeSquareFootage	8816	sqft
CY2015Q1	evfm	Operating Leases Number Of Renewal Options For Extended Terms OperatingLeasesNumberOfRenewalOptionsForExtendedTerms	2	renewal_term
	evfm	Periodic Release Of Security Deposit PeriodicReleaseOfSecurityDeposit	5000	USD
	evfm	Periodic Release Of Security Deposit PeriodicReleaseOfSecurityDeposit	66000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	1606000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	737000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P4Y5M4D
CY2019Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P0Y3M
CY2019Q2	evfm	Loss On Issuance Of Purchase Rights LossOnIssuanceOfPurchaseRights	700000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	8320000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	1185000	USD
CY2020Q4	us-gaap	Loss Contingency Pending Claims Number LossContingencyPendingClaimsNumber	0	claim
CY2020Q1	evfm	Accrued Sublicense Fees AccruedSublicenseFees	1300000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	834000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.12
CY2019Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.12
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2450000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2515000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2171000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2192000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1502000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	10830000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2510000	USD
CY2019Q2	evfm	Compensation Agreement Potential Bonus As A Percent Of Consulting Fees Earned CompensationAgreementPotentialBonusAsAPercentOfConsultingFeesEarned	1
CY2015Q4	evfm	Number Of Sublicenses NumberOfSublicenses	2	agreement
CY2019Q2	evfm	Fair Value Adjustment Of Purchase Rights FairValueAdjustmentOfPurchaseRights	19600000	USD
CY2019Q2	evfm	Warrant Liability WarrantLiability	3600000	USD
CY2019Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3300000	USD
CY2019Q2	evfm	Adjustments To Additional Paidin Capital Reclassification Of Purchase Rights Liability AdjustmentsToAdditionalPaidinCapitalReclassificationOfPurchaseRightsLiability	22800000	USD
CY2020	evfm	Weighted Average Remaining Period WeightedAverageRemainingPeriod	P2Y2M12D
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	10426107	shares
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.54
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	10426107	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020	evfm	Short Swing Profit Disgorgement ShortSwingProfitDisgorgement	200000	USD
CY2020Q4	evfm	Common Stock Reserved Upon Exercise Of Common Stock Warrants CommonStockReservedUponExerciseOfCommonStockWarrants	10426107	shares
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	22918377	shares
CY2020Q1	evfm	Stock Dividends Right StockDividendsRight	1	shares
CY2020Q1	evfm	Stock Dividend Rights Issued Per Share Of Common Stock Held StockDividendRightsIssuedPerShareOfCommonStockHeld	1
CY2020Q1	evfm	Class Of Warrant Or Right Purchase Price ClassOfWarrantOrRightPurchasePrice	17.50
CY2020Q1	evfm	Class Of Warrant Or Right Vesting Term For Beneficial Ownership Threshold ClassOfWarrantOrRightVestingTermForBeneficialOwnershipThreshold	P10D
CY2020Q1	evfm	Class Of Warrant Or Right Right Agreement Beneficial Ownership Threshold ClassOfWarrantOrRightRightAgreementBeneficialOwnershipThreshold	0.32
CY2020Q1	evfm	Class Of Warrant Or Right Vesting Term ClassOfWarrantOrRightVestingTerm	P10D
CY2020Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12697000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8579000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.20
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.50
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	3.51
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	3.94
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	83000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	95000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	47000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	133000	USD
CY2020Q4	evfm	Unrecognized Stock Based Compensation Expense UnrecognizedStockBasedCompensationExpense	9400000	USD
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	200000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.827
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.763
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.006
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.018
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M24D
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	28333	shares
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.030
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	400000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-142305000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-80029000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-142305000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-80029000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	4000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	4000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	4000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	4000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0226
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0037
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0159
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0205
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0076
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0058
CY2020	evfm	Effective Income Tax Rate Reconciliation Deduction Loss On Issuance Of Warrants Percent EffectiveIncomeTaxRateReconciliationDeductionLossOnIssuanceOfWarrantsPercent	-0.0948
CY2019	evfm	Effective Income Tax Rate Reconciliation Deduction Loss On Issuance Of Warrants Percent EffectiveIncomeTaxRateReconciliationDeductionLossOnIssuanceOfWarrantsPercent	-0.0018
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020	evfm	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrants Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantsPercent	0.0404
CY2019	evfm	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrants Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantsPercent	-0.0718
CY2020	evfm	Effective Income Tax Rate Reconciliation Tax Regulation Adjustment Percent EffectiveIncomeTaxRateReconciliationTaxRegulationAdjustmentPercent	-0.0749
CY2019	evfm	Effective Income Tax Rate Reconciliation Tax Regulation Adjustment Percent EffectiveIncomeTaxRateReconciliationTaxRegulationAdjustmentPercent	0
CY2020	evfm	Effective Income Tax Rate Reconciliation Provision To Return EffectiveIncomeTaxRateReconciliationProvisionToReturn	0.0003
CY2019	evfm	Effective Income Tax Rate Reconciliation Provision To Return EffectiveIncomeTaxRateReconciliationProvisionToReturn	-0.0026
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.0045
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.0135
CY2020	evfm	Effective Income Tax Rate Reconciliation Accrual Of Uncertain Tax Positions EffectiveIncomeTaxRateReconciliationAccrualOfUncertainTaxPositions	0.0068
CY2019	evfm	Effective Income Tax Rate Reconciliation Accrual Of Uncertain Tax Positions EffectiveIncomeTaxRateReconciliationAccrualOfUncertainTaxPositions	-0.0042
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.0914
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1205
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1621000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	78124000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	62955000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	538000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	591000	USD
CY2020Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4059000	USD
CY2019Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	6953000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	3840000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	3367000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3230000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	885000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	89791000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	74751000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	34000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	457000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	87713000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	74717000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2413000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2061000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	1177000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	229000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	352000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1465000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2413000	USD
CY2020	evfm	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability Net Operating Loss IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiabilityNetOperatingLoss	5900000	USD
CY2020	evfm	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability Research Tax Credit IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiabilityResearchTaxCredit	-3600000	USD

Files In Submission

Name	View Source	Status
0001618835-21-000040-index-headers.html	Edgar Link	pending
0001618835-21-000040-index.html	Edgar Link	pending
0001618835-21-000040.txt	Edgar Link	pending
0001618835-21-000040-xbrl.zip	Edgar Link	pending
evfm-12312020ex1016evofemb.htm	Edgar Link	pending
evfm-12312020ex1027amended.htm	Edgar Link	pending
evfm-12312020ex1031nonxemp.htm	Edgar Link	pending
evfm-12312020ex211listofre.htm	Edgar Link	pending
evfm-12312020ex23110k.htm	Edgar Link	pending
evfm-12312020ex31110k.htm	Edgar Link	pending
evfm-12312020ex31210k.htm	Edgar Link	pending
evfm-12312020ex32110k.htm	Edgar Link	pending
evfm-20201231.htm	Edgar Link	pending
evfm-20201231.xsd	Edgar Link	pending
evfm-20201231_cal.xml	Edgar Link	unprocessable
evfm-20201231_def.xml	Edgar Link	unprocessable
evfm-20201231_g1.jpg	Edgar Link	pending
evfm-20201231_g2.jpg	Edgar Link	pending
evfm-20201231_g3.jpg	Edgar Link	pending
evfm-20201231_g4.jpg	Edgar Link	pending
evfm-20201231_htm.xml	Edgar Link	completed
evfm-20201231_lab.xml	Edgar Link	unprocessable
evfm-20201231_pre.xml	Edgar Link	unprocessable
evfm-fy2010xkex417descript.htm	Edgar Link	pending
evfmexhibit1030.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EVFM
Evofem Biosciences, Inc. Stock $evfm

2020 Form 10-K Financial Statement

#000161883521000040 Filed on March 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM Evofem Biosciences, Inc. Stock $evfm

2020 Form 10-K Financial Statement

#000161883521000040 Filed on March 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM
Evofem Biosciences, Inc. Stock $evfm